On the 22nd of July, Biovica had fruitful meeting with the FDA regarding Supplement II that discusses the approach for clinical validation of DiviTum. Next step is to document the conclusions from the meeting, which the FDA will review and signoff. This process will take a maximum of 45 days. Thereafter, Supplement II will be completed, [...]
FDA-process and commercialization on track. New study results confirm the potential. Year-End Report (May-January 2018/2019)
SEK thousands Q4 18/19 Q4 17/18 May-April 18/19 May-April 17/18 Net sales 1,715 1,433 3,005 2,723 Operating profit (loss) -8,569 -4,132 -21,718 -17,956 Loss for the period -8,631 -4,176 -21,556 -18,010 Earnings per share, after dilution -0.47 -0.24 -1.18 -1.01
Biovica has a comprehensive study program with DiviTum® to demonstrate the clinical value for cancer patients. Biovica has published a summary brochure in order to share knowledge about results achieved so far with DiviTum® to researchers, oncologists and other stakeholders. The summary describes all clinical studies presented where DiviTum® is used to evaluate response to breast cancer treatment.
Uppsala, Sweden, May 8, 2019: Biovica will participate in the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago May 31-June 4, 2019
The strong results from the previously presented EFECT study have now been published in the scientific, and highly renowned, European Journal of Cancer (impact factor 7.191 which equals to top 3% of scientific journal ranking).
The extra general meeting ("EGM") of Biovica International AB (publ) ("Biovica" or the "Company") was held today on 2 May 2019 and the following resolutions were passed by the meeting. Resolution regarding approval of the board of directors' resolution to issue new class B shares with deviation from the shareholders' preferential rights
Uppsala, Sweden, April 10, 2019: Biovica has agreed on a collaboration with IBL-America for sales of DiviTum® for the research market in the US. The partnership will further increase the commercial activities for this customer segment on the single largest market for Biovica.
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting on Thursday 2 May 2019 at 13.00 pm CET at Baker & McKenzie's premises at Vasagatan 7 in Stockholm. The doors to the meeting will open at 12.45 pm CET. Right to attend and notification Shareholders [...]
Biovica completes a directed new share issue of SEK 60 million and calls for an extraordinary general meeting
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Biovica International AB (publ) (”Biovica” or the ”Company”) has, subject to the extraordinary general meeting subsequent approval and as communicated in the Company’s press release earlier today, resolved to carry out a directed new share issue of Class B Shares at a subscription price of SEK 10 per share. The directed new share issue was substantially over-subscribed with large interest from institutional investors in the Nordics and Europe. Through the directed new share issue and subject to the approval of the extraordinary General Meeting, the Company will receive proceeds amounting to SEK 60 million. The notice convening the EGM will be published separately today.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Biovica International AB (publ) (”Biovica” or the ”Bolaget”) today announces its intention to undertake a directed share issue of Class B shares of SEK 45-60 million to institutional investors. The Company has engaged Pareto Securities AB (”Pareto Securities”) to investigate the conditions for a new issue of Class B shares through a so-called accelerated bookbuilding.